Dipyridamole tid
Small molecule
Dipyridamole tid is one of 44 small molecule programs targeting Restless Legs Syndrome. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Restless Legs Syndrome
#DrugCompanyPhaseTrials
1Neupro
UCBApproved
Mirapex
Boehringer IngelheimApproved
Requip Xl
GGlaxo Dba Glaxosmithkline
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Avelox
BayerApproved
Calciferol
Alnylam PharmaceuticalsApproved
Dostinex
PfizerApproved
Injectafer
AAmerican Regent, Inc.
Approved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Wakix
HHarmony Biosciences Management, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dipyridamole tid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- YYunfeng Xia